

Certificate of Analysis

TLK1, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-938, 14-938-K, 14-938M

Parent Lot # D13JP005N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged, recombinant, human TLK1 full length, expressed by baculovirus in Sf21 insect cells. Purified using immobilized metal affinity chromatography.

Purity 89% by SDS-PAGE and Coomassie blue staining. MW = 91kDa.

Specific Activity (Parent lot# D13JP005N): 293U/mg, where one unit of TLK1, active activity is defined as 1nmol phosphate incorporated into casein per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 0.823mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 0.6–10ng of this lot of enzyme phosphorylated casein in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as TLK1 with the translated sequence listed on page three.



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of TLK1, active.

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Casein:** Use at a final assay concentration of 2mg/ml. Prepare a 20mg/ml stock and add 2.5µl of stock per assay point.
3. **TLK1, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 0.6–10ng per assay point.
4. **[γ -³³P]ATP:** 2.5 x MgAc/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required).

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl of casein.
3. Add **2.5µl (0.6–10ng) TLK1, active.**
4. Add 5µl of dH₂O.
5. Add 10µl of diluted [γ -³³P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5µl of 3% phosphoric acid.
8. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

TLK1 Sequence Information

<u>Protein</u>	human TLK1
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	M31 of the recombinant protein is equivalent to M1 of human TLK1
<u>Accession number</u>	GenBank NM_012290

Recombinant TLK1 amino acid sequence:

```

1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MSVQSSSGSL EGPPSWSQLS TSPTPGSAAA
61 ARSLNHTPP SGRPREGAMD ELHSLDPRRQ ELLEARFTGV ASGSTGSTGS CSVGAKASTN
121 NESSNHSFGS LGSLSDKES EPEKKQSESS RGRKRKAENQ NESSQKSGS GRGHKISDYF
181 EYQGGNGSSP VRGIPPAIRS PQNSHSHSTP SSSVRPNSPS PTALAFGDHP IVQPKQLSFK
241 IIQTDLTMLK LAALESNKIQ DLEKKEGRID DLLRANCDLR RQIDEQQKLL EKYKERLNKC
301 ISMSKKLLIE KSTQEKLSR EKSMQDRLRL GHFTTVRHGA SFTEQWTDGF AFQNLVKQQE
361 WVNQQREDIE RQRKLLAKRK PPTANNSQAP STNSEPKQRK NKAVNGAEND PFVRPNLPQL
421 LTLAEYHEQE EIFKLRLGHL KKEEAETQAE LERLERVRNL HIRELKRINN EDNSQFKDHP
481 TLNERYLLH LLGRGGFSEV YKAFDLYEQR YAAVKIHQLN KSWRDEKKEN YHKHACREYR
541 IHKELDHPRI VKLYDYFSLD TDTFCTVLEY CEGNDLDFYL KQHKLMSEKE ARSIVMQIVN
601 ALRYLNEIKP PIHYDLKPG NILLVDGTAC GEIKITDFGL SKIMDDDSYG VDGMDLTSQG
661 AGTYWYLPPE CFVVGKEPPK ISNKVDVWSV GVIFFQCLYG RKPFGHNQSQ QDILQENTIL
721 KATEVQFPVK PVSSEAKAF IRRCLAYRKE DRFDVHQLAN DPYLLPHMRR SNSSGNLHMA
781 GLTASPTPPS SSIITY

```

Recombinant TLK1 nucleotide sequence:

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaacacctg
61 tatttttcagg gcgcattgga tccggaattc atgagtgtcc aaagtagcag tggaagtgtg
121 gaggggcccgc catcttggtc ccagctctcc acgtctccaa ccccggtctc ggccggcgccg
181 gccagggtccc tgctgaatca cagccgccca tccgggaggc ccagggaagg tgcaatggat
241 gagcttcata gtctggatcc aagaaggcaa gaggatttgg aagctagatt tactggagtt
301 gcaagtggga gcaactggaag tacgggcagt tgcaagtgtg gagctaaagc ctcaacaaat
361 aacgaaagct ctaatcacag ttttggaagc ttgggatctt taagtacaa agaatacagag
421 acaccggaga agaaacaatc ggaatcatcc aggggaagaa agagaaaagc agaaaaccag
481 aatgaaagta gtcagggaag aagatttggg ggacgtggcc acaaaattag cgactatttt
541 gaataccagg gtggaatagg ctcaagtcca gtaaggaggc tacctcctgc aatccgttct
601 cctcaaaatt cacattcaca ttccactcct tcctcatctg ttccaccgaa tagcctttct
661 cctactgcat tagcatttgg ggaccaccct attgtacaac caaagcaatt atccttttaa
721 attattcaga ctgatctcac aatgctgaaa ttagcagcat tagaaagtaa taaaatccag
781 gacctggaag agaaaggagg acgtatagat gatttgctca gggctaactg tgatctcaga
841 cggcaaatag atgaacaaca aaaattactt gaaaaataca aagaacgatt aaataagtgc
901 atatcaatga gcaagaaact tcttattgaa aagagtacac aagaaaagct gtcaagcaga
961 gagaagagta tgcaagatcg attacgcctt gggcacttta caacagttag acatggcgct
1021 tcattttactg aacaatggac agatgggtttt gcatttcaga atctttgtaa gcaacaagaa
1081 tgggtgaatc agcaaggga agatattgaa aggcaggga aacttctagc caaacgcaaa
1141 cctcccacag ctaataattc tcaggcacc tctaccaatt ctgaacaaa acaagggaag
1201 acaaaagcag tcaatggagc agagaatgat ccctttgtta gaccaaattt accacaactg
1261 ttgacttttg cagaatatca tgaacaggaa gaaattttca aacttagact aggacatctc
1321 aaaaagggaag aggcagaaat ccaggcagaa cttgaacgtt tggaaagagt cagaaatctt
1381 cacatacgtg agctgaaaag aataaacaat gaagataatt cacagttcaa agatcaccca

```

Certificate of Analysis

```

1441 acattaaatg aaagatatattt attactttcat ctgcttggtta gaggtggcctt tagtgaagtg
1501 tataaggcctt ttgaccttta tgaacaaaga tatgctgctg tgaagatata tcagcttaat
1561 aaaagctgga gagatgagaa gaaagaaaac taccacaaac atgcctgcag agagtataga
1621 atacacaaag aactggatca cccagaata gttaaactct atgattattt ctccttggat
1681 acagatacgt tttgtacagt gttagaatac tgtgaaggca atgacttga tttctatctg
1741 aagcaacaca agttaatgtc agagaaagaa gctcggctta ttgtaatgca gattgtaaat
1801 gcactaagat atctcaatga gatcaaacc cctattatac attatgatct taagccagga
1861 aacatcctac tggtagatgg aacagcatgt ggtgaaatca aaatcactga ttttggctctg
1921 tccaagatta tggatgatga tagctatggt gtagatggaa tggatctaac ttcccagggg
1981 gcaggcactt actggtatatt acctcctgag tgtttttag taggaaaaga gccaccaaag
2041 atttccaaca aggttgatgt atggtcggtt ggagtcattt tctttcagt tctttatggt
2101 agaaagccat ttggtcaca tcaatctcaa caagacattc ttcaagaaaa tacaatatta
2161 aaagccacag aagtccagtt ccctgtaaaa ccggttgtaa gcagtgaagc caaggcattt
2221 ataagacgct gtttggcata tcgaaaagaa gatcgatttg atgtgcacca gctggcaaat
2281 gaccatacc ttctcccaca catgagaaga tcaaattctt caggaaacct acacatggct
2341 gggctgacag catcccctac acccccttct tcaagcataa ttacttactg a

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services